Ceretrophin Clinical Study

A double-blind, placebo controlled study examining the effects of Ceretrophin™ vs placebo on cognitive function, energy, state-of-mind and mood.

By Dr. Con Stough, Christina Kure, Jo Tarasuik and Luke Downey

BRAIN SCIENCES INSTITUTE SWINBURNE UNIVERSITY, AUSTRALIA Dr. Con Stough BSI Director

Objective

Examine whether Ceretrophin™ enhances performance on tests assessing memory, attention, executive function, alertness, speed of information processing, mood, energy levels, stress and IQ.

Methodology

This study was a Phase III, double blind, placebo controlled exploratory trial with 150 healthy human participants that examined the neuropsychological effects of Ceretrophin™. It was expected that treatment with Ceretrophin™ would produce improvements in cognitive functioning, in particular memory, attention and executive processing. It was also anticipated that Ceretrophin™ would exert additional benefits in improving energy levels, anxiety, depression and stress.

Measures

The Cognitive Drug Research measure (CDR)

Inspection Time

UWIST Mood Adjective Checklist

Spielberger State-Trait Anxiety Inventory

The General Health Questionnaire (GHQ)

IQ: Raven Progressive Matrices

Results

Click Here to download the Ceretrophin™ Technical Report

Peer Review Publications

Psychopharmacology

Human Psychopharmacology

Neuroimage

Archives of General Psychiatry

Psychological Medicine

International Journal of Neuropsychopharmacology

Shop Now